Evidence map›Paper›PMID 39963432›Full record

ReviewFrontiers in medicine2025

Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.

Rupal Dhariwal, Mukul Jain, Yaser Rafiq Mir, Abhayveer Singh, Bhavik Jain, Pankaj Kumar, Mohd Tariq, Devvret Verma, Khemraj Deshmukh, Virendra Kumar Yadav and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. A patent review of cyclin-dependent kinase 5 (CDK5) inhibitors (1999-2025).Frontiers in bioengineering and biotechnology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Nano-structured strategies in combatting neurodegeneration.Frontiers in bioengineering and biotechnology · 2025
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rupal DhariwalResearch and Development Cell, Parul University, Vadodara, India.
Mukul JainResearch and Development Cell, Parul University, Vadodara, India.
Yaser Rafiq MirDepartment of Biotechnology, Baba Ghulam Shah Badshah University, Rajouri, India.
Abhayveer SinghCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India.
Bhavik JainChitkara Centre for Research and Development, Chitkara University, Baddi, India.
Pankaj KumarDepartment of Environmental Science, Parul Institute of Applied Sciences, Parul University, Vadodara, India.
Mohd TariqDepartment of Life Sciences, Parul Institute of Applied Sciences, Parul University, Vadodara, India.
Devvret VermaDepartment of Biotechnology, Graphic Era (Deemed to be University), Dehradun, India.
Khemraj DeshmukhDepartment of Biomedical Engineering, Parul Institute of Technology, Parul University, Vadodara, India.
Virendra Kumar YadavMarwadi University Research Center, Marwadi University, Rajkot, India.
Tabarak MalikDepartment of Biomedical Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases, characterized by progressive neuronal loss and cognitive impairments, pose a significant global health challenge. This study explores the potential of nanotherapeutics as a promising approach to enhance drug delivery across physiological barriers, particularly the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (B-CSFB). By employing nanoparticles, this research aims to address critical challenges in the diagnosis and treatment of conditions such as Alzheimer's, Parkinson's, and Huntington's diseases. The multifactorial nature of these disorders necessitates innovative solutions that leverage nanomedicine to improve drug solubility, circulation time, and targeted delivery while minimizing off-target effects. The findings underscore the importance of advancing nanomedicine applications to develop effective therapeutic strategies that can alleviate the burden of neurodegenerative diseases on individuals and healthcare systems.

Indexed as

nanotherapeuticsneurodegenerationNeurodegenerative diseasesmall moleculestargeted delivery

Identifiers

PMID39963432
PMCPMC11831571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.